No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
77 |
4. Check minimum number of eventsNone |
77 |
5. Include endpointsNone |
77 |
6. Filter based on genotype QC (FinnGen only) |
72 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E78
- Name in latin
- Deficientia lipoproteinorum
Similar endpoints
↥List of similar endpoints to
Lipoprotein deficiency
based on the number of shared cases.
Similar with more cases:
- Disorders of lipoprotein metabolism and other lipidaemias
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 675 | 279 | 394 |
| Only index persons | 614 | 256 | 358 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 65.75 | 68.29 | 63.94 |
| Only index persons | 65.71 | 68.17 | 63.94 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 72 | 24 | 48 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 60.90 | 60.49 | 61.11 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 77
- Matched controls
- 770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E78.63
ICD-10 Finland
Low HDL syndrome
+∞
53.5
45
*
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
8.1
14.6
24
41
C10AA05
ATC
atorvastatin; oral
5.9
13.3
51
191
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
5.5
11.8
33
93
E78.69
ICD-10 Finland
Lipoprotein deficiency, other or unspecified
+∞
11.8
11
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
5.1
10.6
31
90
T90
ICPC
Diabetes non-insulin dependent
4.8
9.7
30
90
E78.6
ICD-10 Finland
Lipoprotein deficiency
+∞
9.6
9
*
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
+∞
9.6
9
*
C07AB07
ATC
bisoprolol; oral
4.4
8.4
55
280
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
8.2
25
73
103
Kela drug reimbursment
Diabetes, insulin-treated
4.1
8.2
33
119
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
8.0
50
243
SPAT1262
SPAT
Handing over of treatment supplies
4.7
7.9
22
60
E78.61
ICD-10 Finland
Abetalipoproteinaemia
+∞
7.4
7
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
7.2
21
59
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
44.1
6.9
8
*
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
9.5
6.6
13
16
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.8
6.5
25
86
E87.6
ICD-10 Finland
Hypokalaemia
20.1
6.4
9
5
N08.4*E78.6
ICD-10 Finland
Glomerular disorders in lecithin cholesterol acyltransferase deficiency
+∞
6.3
6
*
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
3.7
6.2
26
94
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.4
6.2
18
50
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
4.0
6.1
21
66
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
153
3.36
6.26
5.9
3.1
14.29
5.11
mg/mmol
0.52
22
100
49
266
3.32
6.05
8.1
5.7
1.21
1.21
mmol/l
0.04
37
229
49
276
3.13
5.50
21.2
11.5
1.32
1.22
inr
0.27
19
79
40
206
2.96
5.19
2.4
2.0
91.37
96.24
pmol/l
0.28
23
113
44
252
2.74
4.50
6.8
4.7
1.22
1.21
mmol/l
0.30
44
229
29
134
2.87
4.47
2.0
1.5
2.74
1.40
mmol/l
1.13
22
110
18
63
3.42
4.42
4.2
3.2
—
—
—
0
0
25
111
2.85
4.11
2.4
1.8
352.00
420.60
pmol/l
0.75
19
101
68
521
3.61
4.10
5.5
4.3
2.03
1.93
mu/l
0.28
60
466
21
93
2.73
3.41
2.3
4.1
0.86
0.82
mmol/l
0.82
21
86
43
276
2.26
3.06
4.6
3.4
0.00
0.00
estimate
-0.00
12
49
8
17
5.12
3.01
1.0
1.6
—
—
—
0
0
42
273
2.18
2.83
4.5
3.4
0.00
0.00
estimate
-0.00
12
56
36
222
2.17
2.75
6.4
3.6
23.89
55.16
ng/l
0.98
28
159
29
168
2.16
2.56
3.3
2.6
0.11
0.44
e6/l
1.33
20
120
56
420
2.22
2.49
4.7
3.7
15.13
14.78
pmol/l
0.50
51
376
41
274
2.06
2.48
6.2
4.4
0.00
0.00
estimate
-0.00
12
50
34
217
2.02
2.29
4.3
3.5
—
—
—
0
0
10
36
3.04
2.23
1.4
1.7
—
—
—
0
0
72
628
3.25
2.17
26.9
15.9
88.93
79.19
umol/l
0.93
72
628
63
509
2.31
2.13
22.5
16.1
15.93
15.23
%
0.30
63
499
70
601
2.81
2.13
23.3
13.5
25.42
24.06
mg/l
0.13
61
470
28
174
1.96
1.98
3.3
3.0
958.81
1228.93
ng/l
0.28
21
148
70
608
2.66
1.97
6.8
4.6
2.40
2.77
mmol/l
2.31
63
557
9
34
2.86
1.94
3.6
6.4
23.06
24.13
mmol/l
—
9
34
68
594
2.24
1.68
6.5
4.2
1.07
1.43
mmol/l
7.45
60
543
70
618
2.46
1.67
27.0
14.9
4.01
4.00
mmol/l
0.15
70
596
70
615
2.52
1.67
26.8
14.8
139.70
139.76
mmol/l
0.08
70
595
68
597
2.19
1.54
6.4
4.2
4.12
4.63
mmol/l
3.08
62
550
67
579
2.21
1.54
6.2
4.4
6.76
5.95
mmol/l
1.68
59
529
24
154
1.81
1.50
4.8
3.8
0.00
0.00
estimate
-0.00
12
47
11
53
2.25
1.47
7.8
2.8
-0.67
1.67
mmol/l
1.47
11
41
7
29
2.55
1.43
2.9
2.1
0.74
1.52
%
—
7
29
67
584
2.13
1.42
5.6
3.8
2.17
1.31
mmol/l
2.41
61
529
16
95
1.86
1.26
3.1
2.5
2.57
0.53
e6/l
—
7
46
35
261
1.63
1.24
4.2
2.4
—
—
—
0
0
13
73
1.94
1.19
2.5
4.1
105.46
104.66
mmol/l
0.41
13
73
5
21
2.47
1.11
1.0
1.8
—
—
—
0
0
15
96
1.70
0.93
2.3
2.1
—
—
—
0
0
16
105
1.66
0.91
3.3
2.4
1.49
0.65
e6/l
—
7
56
11
66
1.78
0.84
1.9
2.5
0.18
0.21
g/l
0.62
11
60
6
33
1.89
0.81
1.5
1.3
—
—
—
0
0
5
24
2.16
0.76
1.0
2.8
23.86
23.82
mmol/l
—
5
24
5
27
1.91
0.70
6.4
2.7
56.38
54.33
%
—
5
27
6
39
1.58
0.54
1.8
1.9
—
—
—
0
0
19
149
1.37
0.48
4.6
2.1
—
—
—
0
0
7
49
1.47
0.47
2.0
2.3
27.00
32.50
u/l
—
7
42
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
16
126
1.34
0.39
1.9
1.6
1.04
0.86
mg/l
—
10
94
9
70
1.32
0.38
1.2
2.0
—
—
—
0
0
5
76
0.63
0.38
4.6
8.0
—
—
—
0
0
6
46
1.33
0.34
2.3
1.6
—
—
—
0
0
5
37
1.38
0.24
2.2
3.3
0.68
0.69
%
—
5
37
27
242
1.18
0.22
4.0
4.5
25.91
21.75
%
0.62
15
113
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
183.79
—
0
10
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
37
345
1.14
0.17
2.9
3.1
—
—
—
0
0
8
71
1.14
0.17
1.4
2.1
—
—
—
0
0
7
86
0.80
0.15
1.7
1.6
—
—
—
0
0
12
107
1.14
0.09
1.2
1.3
0.96
2.61
u/ml
—
5
32
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
6
66
0.90
0.00
4.2
4.5
2.68
6.02
ug/l
—
6
57
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.0
—
26.46
—
0
8
0
5
0.00
-0.00
0.0
1.8
—
13.00
—
0
5
6
65
0.92
-0.00
1.3
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
18.99
—
0
7
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_LIPODEF and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_LIPODEF | 2.042 [1.38, 3.01] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.377 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 249 females with E4_LIPODEF died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_LIPODEF | 2.28 [1.56, 3.33] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 343 males with E4_LIPODEF died.
Mortality risk
Mortality risk for people of age
years, who have E4_LIPODEF.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.166% | 0.293% |
| 5 | 1.201% | 2.475% |
| 10 | 3.159% | 6.698% |
| 15 | 5.917% | 12.738% |
| 20 | 10.015% | 20.311% |
Relationships between endpoints
↥Index endpoint: E4_LIPODEF – Lipoprotein deficiency
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data